CN107961247B - Application of badger oil in preparing medicine for treating liver injury - Google Patents
Application of badger oil in preparing medicine for treating liver injury Download PDFInfo
- Publication number
- CN107961247B CN107961247B CN201710638551.4A CN201710638551A CN107961247B CN 107961247 B CN107961247 B CN 107961247B CN 201710638551 A CN201710638551 A CN 201710638551A CN 107961247 B CN107961247 B CN 107961247B
- Authority
- CN
- China
- Prior art keywords
- liver injury
- badger
- liver
- mice
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000282346 Meles meles Species 0.000 title claims abstract description 41
- 206010067125 Liver injury Diseases 0.000 title claims abstract description 36
- 231100000753 hepatic injury Toxicity 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 title claims abstract description 22
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims abstract description 50
- 238000012545 processing Methods 0.000 claims description 3
- 210000004003 subcutaneous fat Anatomy 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 30
- 229940079593 drug Drugs 0.000 abstract description 12
- 238000011084 recovery Methods 0.000 abstract description 11
- 238000002474 experimental method Methods 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 6
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 238000012827 research and development Methods 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 34
- 210000004185 liver Anatomy 0.000 description 24
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 22
- 239000003921 oil Substances 0.000 description 22
- 235000019198 oils Nutrition 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 12
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 11
- 239000004305 biphenyl Substances 0.000 description 11
- 235000010290 biphenyl Nutrition 0.000 description 11
- 229940118019 malondialdehyde Drugs 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 125000003473 lipid group Chemical group 0.000 description 5
- 230000003859 lipid peroxidation Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 231100000439 acute liver injury Toxicity 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000349731 Afzelia bipindensis Species 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HSSYVKMJJLDTKZ-UHFFFAOYSA-N 3-phenylphthalic acid Chemical compound OC(=O)C1=CC=CC(C=2C=CC=CC=2)=C1C(O)=O HSSYVKMJJLDTKZ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 241001504654 Mustela nivalis Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 201000007772 internal hemorrhoid Diseases 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000013403 specialized food Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000010463 virgin olive oil Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the field of food and medicine, in particular to application of badger fat in preparing medicines or health-care foods for treating liver injury. Experiments show that the badger oil has recovery effect on mouse liver injury caused by carbon tetrachloride, and the higher the concentration is, the more obvious the inhibition effect is, and the badger oil has treatment effect on liver injury diseases, so that a certain experimental basis is provided for the research and development of new liver injury medicines and the development of health products.
Description
Technical Field
The invention relates to the field of food and medicine, in particular to application of badger fat in preparing medicines or health-care foods for treating liver injury.
Background
In the prior art, badger is a kind of Chinese characterMelesmeles) Also called badgers, tendons, grazing, belongs to a large species of weasel. The back of the badger grows from head to tail with long and thick needle hair, and the color is black brown mixed with white and appears brown gray. Coarse and solid body shape, short limbs, short and round earshells, small eyes, tip of nose and thick neck. The badger oil is prepared by processing and decocting subcutaneous fat of badgers, is one of important medicinal materials for treating scalds in China, and has the effects of tonifying middle-jiao and Qi, moisturizing skin and promoting granulation, and detoxifying and detumescence. Can be used for treating burn, scald, induration, radioactive skin injury, viral herpes, alopecia, swelling and pain of internal hemorrhoid and external hemorrhoid, and can be used for treating intestinal obstruction, sand knot, gastric ulcer, uterine prolapse and hemiplegia by oral administration.
Liver disease is currently the major disease threatening human health, with a high incidence and mortality rate. Liver cells are important components of liver, and trauma, bacteria, viruses, alcohol and drugs can damage liver cells, thereby causing liver dysfunction, namely liver injury, and the degree of liver injury mainly refers to the degree of necrosis of liver cells. In recent years, the incidence of viral hepatitis and the number of carriers have been continuously increased, and with the change of life style, the incidence of fatty liver, alcoholic liver disease and drug-induced liver injury is also increasing. Based on the situation, the development of liver protection drugs and the evaluation of the liver protection effect of the drugs are always hot spots for the research of liver disease drugs at home and abroad.
Disclosure of Invention
The invention aims to provide a novel application of badger oil in medicine and health care food, namely application of badger oil in preparation of medicines or health care food for treating liver injury.
The technical scheme of the invention is as follows: the application of adeps melis in preparing medicine or health food for treating liver injury. The badger oil is prepared by processing and decocting subcutaneous fat of badger.
The badger oil is used as main active ingredient to prepare the medicine for treating liver injury, which can be single or compound preparation. Can be added with one or more active ingredients with synergistic or auxiliary effects, and can be added with pharmaceutically acceptable carrier such as excipient or adjuvant, and can be made into tablet, capsule (soft capsule), granule, powder, pill, liquid preparation or other conventional preparation.
The adeps melis as main active ingredient, and can be added into health food. The dosage form is not limited.
The invention has the advantages that: experiments show that the badger oil has recovery effect on mouse liver injury caused by carbon tetrachloride, and the higher the concentration is, the more obvious the inhibition effect is, and the badger oil has treatment effect on liver injury diseases, so that a certain experimental basis is provided for the research and development of new liver injury medicines and the development of health products.
Embodiments of the present invention will be described in further detail with reference to examples.
Detailed Description
Examples
The application of adeps melis in preparing medicine or health food for treating liver injury.
Experiment example(s)
Badger oil has protective effect on mice with carbon tetrachloride liver injury.
Experimental materials and instruments
1.1 laboratory animals
Male mice of Kunming species, body weight (20+ -2) g, supplied by Changchun Biotechnology research all of the company Limited, quality qualifications were SCXK 2011-0003.
1.2 Experimental reagents
Badger oil is purchased from Tonghua Natural specialty food Co; carbon tetrachloride, bodi chemical Co., ltd; super virgin olive oil, shandong Luhua group Co., ltd; normal saline, dubang pharmaceutical industry, inc; the bifendate dripping pill, beijing co-ordination pharmaceutical factory; total superoxide dismutase (T-SOD) test box, nanjing builds the institute of bioengineering; malondialdehyde (MDA) test box, nanjing builds the institute of bioengineering; protein quantitative test box, nanjing builds up bioengineering institute; glutamic-oxaloacetic transaminase (AST) test box, nanjing builds up the institute of biological engineering; glutamic pyruvic transaminase (ALT) test box and Nanjing build institute of biological engineering; picric acid, tianjin, denou chemical Co., ltd; glacial acetic acid, MIEuro chemical reagent Co., ltd.
1.3 laboratory apparatus
Semi-automatic biochemical analyzer: model AT-658LUS type, chengdu instruments and equipment Co., ltd; ultraviolet visible spectrophotometer: model UV-1200S, soaring instruments (Shanghai) limited; heat collection type constant temperature magnetic stirrer: model DF-101S, consolidating the Limited liability company of the Chinese instruments in the market; high-speed centrifuge: model TG16K, long Sha Dongwang laboratory instruments inc; tissue refiner: model FSH-2, manufactured by Rong instruments, inc. of gold altar, jiangsu province; precision electronic balance: model JA2003, shanghai Hengping scientific instruments Co., ltd; animal balance: beijing 00000246, sidoriko instruments (Beijing).
Experimental method
2.1 Experimental grouping
60 mice were serpentine groups into 6 groups, which were labeled simultaneously for differentiation. And randomly determining 6 groups of mice as a blank control group, a model group, a biphenyl double fat group and a badger oil low, medium and high dose group.
2.2 feeding conditions
Mice were normally fed water daily, naturally illuminated and kept in a clean feeding environment, and after 24h adaptation, the experiment was started.
2.3 dosage of drug
The mass concentration of the biphenyldicarboxylate to the mice per day is 1mg/10g, and the biphenyldicarboxylate is administered according to 0.1ml/10 g. The badger oil is infused with 0.2ml/10g, 0.1ml/10g and 0.05ml/10g of the badger oil per day in high, medium and low dosage groups, and the blank control group and the model group are infused with 0.2ml/10g of physiological saline per day for 12 days; while the other 5 groups except the normal group were respectively perfused with 0.1ml of 10% carbon tetrachloride-olive oil solution at 6, 9 and 12 d.
2.4 Experimental methods
After the 12d last molding of each group of mice, after 24h of no water forbidden, the mice are subjected to head breaking and blood taking at 1600r/min and centrifuging for 10min to prepare serum, and the ALT and AST contents in the serum are measured. Taking out the liver, flushing out residual blood with normal saline, wiping the residual blood with filter paper, weighing, and according to the formula: liver index was calculated by multiplying liver weight/mouse weight by 100%, grinding with a tissue homogenizer, adding physiological saline to prepare 10% liver homogenate, and measuring the content of liver MDA and SOD.
2.5 data statistics
To be used forThe data results are expressed in form, the group comparison is performed using t-test, and experimental data is processed using SPSS software (version 13.0, SPSS Inc., chicago, USA).
Experimental results
3.1 general for mice influence of features
The living state and weight growth of the mice in each group are normal, the food consumption and water intake of the mice in each administration group are not obviously different from those of the mice in the blank control group, the model group is slightly listless, and the mice in the administration group are slightly active.
3.2 Effect on AST and ALT content in serum
Mouse serum was taken, the procedure was performed according to the instructions of AST and ALT kit, absorbance was measured using a semi-automatic biochemical analyzer, and the contents of AST and ALT in serum were calculated according to the instructions of kit use, and the results are shown in Table 1.
Glutamic-oxaloacetic transaminase and glutamic-pyruvic transaminase are cytoplasmic enzymes, and the content of the glutamic-oxaloacetic transaminase and the glutamic-pyruvic transaminase in serum is small; once the cells are damaged, the cell membrane breaks down and enters the blood and the serum content increases. The experimental result shows that compared with the glutamic-oxaloacetic transaminase content in the serum of the mice of the model group, the blank control group has extremely obvious performance difference (p is less than 0.01), which indicates that the modeling of the hepatic injury of the mice caused by carbon tetrachloride is successful; the performance difference of the biphenyl double lipid groups is extremely obvious (p is less than 0.01), which proves that the biphenyl double lipid has obvious recovery effect on mouse liver injury caused by carbon tetrachloride; the low, medium and high dosage groups of the badger oil have the inhibiting effect on AST content in serum of mice, and the dosage groups of the medium and high dosage groups show significant difference (p is less than 0.05), which indicates that the badger oil has the recovering effect on liver injury of mice caused by carbon tetrachloride, and the higher the concentration is, the more obvious the inhibiting effect is. Compared with the glutamic pyruvic transaminase content in the serum of the mice in the model group, the blank control group has extremely obvious difference (p is less than 0.01), which proves that the modeling of the hepatic injury of the mice caused by carbon tetrachloride is successful; the performance difference of the biphenyl double lipid groups is extremely obvious (p is less than 0.01), which proves that the biphenyl double lipid has obvious recovery effect on mouse liver injury caused by carbon tetrachloride; the low, medium and high dosage groups of the badger oil have inhibition effect on ALT content in serum of mice, and the difference of the low, medium and high dosage groups is very obvious (p is less than 0.01), which indicates that the badger oil has recovery effect on liver injury of mice caused by carbon tetrachloride, and the higher the concentration is, the more obvious the inhibition effect is.
3.3 effects on MDA and SOD levels in liver homogenates.
The liver homogenate of the mice was taken, absorbance was measured using a spectrophotometer according to the method of operation of the MDA and SOD kit, and the contents of MDA and SOD in the liver homogenate were calculated according to the kit instructions, and the results are shown in table 2.
Malondialdehyde is the major product of lipid peroxidation and can severely damage hepatocyte structure, leading to further hepatocyte damage, in amounts reflecting the level of lipid peroxide in the body, also being a damaging factor. The liver MDA can not only reflect the lipid peroxidation strength of liver cells and the attack degree of free radicals on cells, but also reflect the damage degree of the liver. The experimental result shows that compared with the model group, the blank control group shows significant difference (p is less than 0.05), which indicates that the mouse liver injury caused by carbon tetrachloride is successful in modeling; the biphenyl double lipid groups show significant differences (p is less than 0.05), which indicates that the biphenyl double lipid has obvious recovery effect on mouse liver injury caused by carbon tetrachloride; the low, medium and high dosage groups of the badger fat have the inhibiting effect on the MDA content in the liver homogenate of the mice, and the high dosage groups show significant difference (p is less than 0.05), which indicates that the badger fat has the recovering effect on the liver injury of the mice caused by the carbon tetrachloride, and the higher the concentration is, the more obvious the inhibiting effect is.
Superoxide dismutase is one of endogenous protective enzymes of organisms, and can remove free radicals and prevent hepatic cell injury caused by lipid peroxidation. The content of malondialdehyde is increased, so that the activity of superoxide dismutase is reduced, and the content is reduced. The experimental result shows that compared with the model group, the blank control group has extremely obvious performance difference (p is less than 0.01), which indicates that the modeling of the hepatic injury of the mice caused by carbon tetrachloride is successful; the biphenyl double lipid groups show significant differences (p is less than 0.05), which indicates that the biphenyl double lipid has recovery effect on mouse liver injury caused by carbon tetrachloride; the low, medium and high dosage groups of the badger fat can increase the SOD content in the liver homogenate of the mice, and the high dosage group of the badger fat shows significant difference (p is less than 0.05), which indicates that the badger fat has recovery effect on the liver injury of the mice caused by carbon tetrachloride, and the higher the concentration is, the more obvious the recovery effect is.
3.4 Effect on liver index
Liver index was calculated according to the method of 2.4 and the results are shown in Table 3.
The liver of the mice has obvious swelling phenomenon after carbon tetrachloride is injected, and experimental results show that compared with the liver index of a model group, the blank control group has extremely obvious performance difference (p is less than 0.01), which indicates that the modeling of the liver injury of the mice caused by carbon tetrachloride is successful; the biphenyl double lipid groups show significant differences (p is less than 0.05), which indicates that the biphenyl double lipid has recovery effect on mouse liver injury caused by carbon tetrachloride; the low, medium and high dosage groups of the badger oil have inhibition effect on the liver indexes of mice, and the high dosage groups show significant differences (p is less than 0.05), which indicates that the badger oil has recovery effect on the liver injury of mice caused by carbon tetrachloride, and the higher the concentration is, the more obvious the inhibition effect is.
Discussion of the invention
In recent years, the number of people suffering from liver diseases is increasing, carbon tetrachloride has severe toxicity to liver cells, and the induced acute liver injury is a common experimental model for researching liver protection drugs 450 Is converted into trichloromethyl groups and forms free radicals, which after production attack cell membranes and membrane-like substances such as mitochondria and endoplasmic reticulum, cause lipid peroxidation, lead to a disturbance of the homeostasis of the calcium, and finally cause cell death. Recent researches show that liver injury is a complex process participated by multiple factors, and free radical injury and lipid peroxidation play an important role in liver diseases, so that the research on liver protection medicines is also important. Experimental results show that each dosage group of the badger fat oil can inhibit the increase of AST and ALT contents in serum of mice with acute liver injury caused by carbon tetrachloride, can obviously reduce the increase of MDA contents of the liver of the mice with acute liver injury caused by CCl4, and can also improve the SOD contents of the injured liver. The badger oil has the protection effect on mice acute liver injury caused by carbon tetrachloride by each dose, and the high dose has the best effect. Therefore, the badger fat oil has a certain development prospect as a novel liver-protecting medicine.
Claims (2)
1. The application of the badger oil as the only active component in preparing the medicine for treating the liver injury caused by carbon tetrachloride is characterized in that the administration dosage of the badger oil is 0.2ml/10g.
2. The use according to claim 1, wherein the badger fat is prepared by processing and decocting the subcutaneous fat of the badger.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710638551.4A CN107961247B (en) | 2017-07-31 | 2017-07-31 | Application of badger oil in preparing medicine for treating liver injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710638551.4A CN107961247B (en) | 2017-07-31 | 2017-07-31 | Application of badger oil in preparing medicine for treating liver injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107961247A CN107961247A (en) | 2018-04-27 |
| CN107961247B true CN107961247B (en) | 2023-10-10 |
Family
ID=61996653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710638551.4A Active CN107961247B (en) | 2017-07-31 | 2017-07-31 | Application of badger oil in preparing medicine for treating liver injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107961247B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152365A (en) * | 2007-09-28 | 2008-04-02 | 吕世星 | Chinese medicinal herb pill for treating hepatitis b |
-
2017
- 2017-07-31 CN CN201710638551.4A patent/CN107961247B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152365A (en) * | 2007-09-28 | 2008-04-02 | 吕世星 | Chinese medicinal herb pill for treating hepatitis b |
Non-Patent Citations (3)
| Title |
|---|
| 沈勇，等.方58.《肝炎中医诊疗养护》.人民军医出版社,2007,第166页. * |
| 獾子油的化学成分研究;朱琳，等;《中国实验方剂学杂志》;20131130;第19卷(第22期);第108-110页 * |
| 獾油的药学研究概况;杨花，等;《宁夏农林科技》;20110430;第52卷(第04期);第61-62页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107961247A (en) | 2018-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pitchaipillai et al. | In vitro antidiabetic activity of ethanolic leaf extract of bruguiera Cylindrica L.–glucose uptake by yeast cells method | |
| KR101533600B1 (en) | Manufacturing Method for Allomyrina dichotoma extract having anti-Obesity effect and Anti-Obesity Composition Containing the same | |
| Faridi et al. | Beneficial effects of hydroalcoholic extract of saffron in alleviating experimental autoimmune diabetes in C57bl/6 mice | |
| CN105722974A (en) | Method for inducing pluripotent stem cells and pluripotent stem cells prepared by said method | |
| CN105063140A (en) | Preparation method and application of pelodiscus sinensis collagen peptide | |
| CN111184774B (en) | Corydalis saxicola bunting and application of corydalis saxicola bunting preparation in preparation of drug for treating non-alcoholic fatty liver disease | |
| CN107961247B (en) | Application of badger oil in preparing medicine for treating liver injury | |
| CN101972334B (en) | Traditional Chinese medicine preparation for preventing and treating infantile eczema and preparation method thereof | |
| CN105012826A (en) | Alpinia oxyphylla leaf extract and preparation method and application thereof | |
| CN103977014B (en) | A kind of medicine being applied to treat metabolic syndrome | |
| CN101503721B (en) | Method for extracting swan-mussel polysaccharide | |
| CN110693873B (en) | Preparation and application of rabdosia rubescens active ingredient composition | |
| Longkumer et al. | EVALUATION OF LIPID PROFILE IN STREPTOZOTOCIN-INDUCED DIABETIC ZEBRAFISH, TREATED WITH C-PHYCOCYANIN AND EPIGALLOCATECHIN GALLATE. | |
| CN102342962A (en) | Application of extracts from Portulaca oleracea L. in preparation of anti-liver injury medicines and health foods | |
| CN111544440A (en) | Application of diosmin and composition in preparation of anti-obesity product | |
| CN113402585A (en) | Oyster peptide and application thereof in alcoholic liver injury | |
| CN101596268B (en) | Application of garlic total saponin in preparing medicaments and foods for resisting oxidative stress damage | |
| CN105434895A (en) | Gastrodia elata rhodiola rosea cream and preparation method thereof | |
| CN110038090A (en) | A kind of compound celery oil self-emulsifying soft capsule and preparation method thereof with antigout effect | |
| CN109021135A (en) | A kind of codonopsis pilosula var. modesta polysaccharide formulation and preparation method thereof | |
| CN102210725B (en) | Application of hypericum japonicum thunb general flavone in preparing medicament for treating hepatic fibrosis | |
| CN115350170B (en) | Application of taurine in preparation of medicine for improving antiviral parotitis capability of Chinese softshell turtles | |
| CN114767760B (en) | A composition with liver protecting effect | |
| CN107648482A (en) | A kind of Chinese medicine composition for being used to treat nerve degenerative diseases | |
| CN111297887B (en) | Preparation method and application of liver-protecting active component of Yunnan ginseng |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20230908 Address after: 134001 D3033, 2nd Floor, Jiangnan Middle East Night City, Dongchang District, Tonghua City, Jilin Province Applicant after: Wang Wei Applicant after: TONGHUA NORMAL University Address before: School of Life Sciences, Tonghua Normal University, No. 950 Yucai Road, Dongchang District, Tonghua City, Jilin Province, 134000 Applicant before: He Xiaoyan |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |